GRIN3A: A Potential Drug Target and Biomarker for Psychiatric Disorders

Target Name: GRIN3A

NCBI ID: G116443

GRIN3A

GRIN3A: A Potential Drug Target and Biomarker for Psychiatric Disorders

Glutamate is a neurotransmitter that plays a crucial role in communication between neurons and glial cells in the central nervous system (CNS). The N-methyl-D-aspartate (NMDA) receptor subunit 3A (GRIN3A) is an important protein that belongs to the NMDA receptor subfamily. It is expressed in various tissues and cell types throughout the body and plays a significant role in neurotransmission, including the regulation of pain, anxiety, and learning. In this article, we will discuss GRIN3A as a drug target and its potential utility as a biomarker for various psychiatric and neurological disorders.

Drug Target Potential

GRIN3A has been identified as a potential drug target due to its unique structure and its involvement in multiple cellular processes. TheGRIN3A protein is composed of 114 amino acid residues and has a calculated molecular weight of 13.9 kDa. It is a monomer and has a single transmembrane region. The GRIN3A protein is expressed in the brain and is also found in other tissues, including the heart, pancreas, and liver.

GRIN3A is involved in the regulation of neurotransmitter release from synapses, which is critical for the function of the nervous system. Studies have shown that GRIN3A is involved in the regulation of glutamate release and that it plays a role in the modulation of pain perception.

GRIN3A has also been shown to be involved in the regulation of anxiety and depression. Studies have shown that GRIN3A is involved in the regulation of the release of neurotransmitters, including dopamine and serotonin, which are involved in the regulation of mood and anxiety.

GRIN3A has also been shown to be involved in the regulation of learning and memory. Studies have shown that GRIN3A is involved in the regulation of the release of neurotransmitters, including N-methyl-D-aspartate (NMDA), which is involved in the regulation of learning and memory.

GRIN3A is also a potential biomarker for various psychiatric and neurological disorders. Studies have shown that GRIN3A is involved in the regulation of neurotransmission in individuals with depression, anxiety, and schizophrenia.

Biomarker Potential

GRIN3A has the potential to be used as a biomarker for various psychiatric and neurological disorders. Studies have shown that GRIN3A is involved in the regulation of neurotransmission in individuals with depression, anxiety, and schizophrenia.

GRIN3A is involved in the regulation of the release of neurotransmitters, including dopamine and serotonin, which are involved in the regulation of mood and anxiety. Studies have shown that individuals with depression and anxiety have lower levels of GRIN3A than healthy individuals.

GRIN3A is also involved in the regulation of the release of NMDA, which is involved in the regulation of learning and memory. Studies have shown that individuals with depression and anxiety have lower levels of NMDA than healthy individuals.

Conclusion

In conclusion, GRIN3A is a protein that is involved in the regulation of neurotransmission and has the potential to be used as a drug target for various psychiatric and neurological disorders. Studies have shown that GRIN3A is involved in the regulation of the release of neurotransmitters, including dopamine and serotonin, which are involved in the regulation of mood and anxiety. Additionally, studies have shown that GRIN3A is involved in the regulation of the release of NMDA, which is involved in the regulation of learning and memory. GRIN3A also has the potential to be used as a biomarker for various psychiatric and neurological disorders. Further research is needed to fully understand the role of GRIN3A in

Protein Name: Glutamate Ionotropic Receptor NMDA Type Subunit 3A

Functions: NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. During the development of neural circuits, plays a role in the synaptic refinement period, restricting spine maturation and growth. By competing with GIT1 interaction with ARHGEF7/beta-PIX, may reduce GIT1/ARHGEF7-regulated local activation of RAC1, hence affecting signaling and limiting the maturation and growth of inactive synapses. May also play a role in PPP2CB-NMDAR mediated signaling mechanism

The "GRIN3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRIN3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets